Dr. Aaron J. Scott, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
3838 N Campbell Ave
Tucson, AZ 85719
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 159
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Arizona College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AZ license 52153 -
Internal Medicine Physician
AZ license 52153
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner - University Medical Center Tucson Campus Tucson, AZ
- Banner-University Medical Center South Campus Tucson, AZ
Medical groups
- Banner-University Medical Group (1,072 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 159
- Services billed
- 466
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 168 | 72 |
| Established patient office or other outpatient visit, 30-39 minutes | 139 | 77 |
| Established patient office or other outpatient visit, 20-29 minutes | 34 | 32 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 22 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Tucson, AZ | 90 |
| Lonsurf (trifluridine/tipiracil hcl) | 77 |
| Ondansetron Hcl Other prescribers in Tucson, AZ | 57 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Tucson, AZ | 47 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Tucson, AZ | 39 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Tucson, AZ | 34 |
| Oxycodone Hcl Other prescribers in Tucson, AZ | 34 |
| Eliquis (apixaban) Other prescribers in Tucson, AZ | 34 |
| Potassium Chloride Other prescribers in Tucson, AZ | 30 |
| Lorazepam Other prescribers in Tucson, AZ | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $127 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $54.13 |
|---|---|
| Novartis Pharmaceuticals Corporation | $48.50 |
| Daiichi Sankyo Inc. | $20.36 |
| Pfizer Inc. | $3.70 |
| Food and Beverage | $123 |
|---|---|
| Education | $3.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Feb 3, 2025 | Education in-kind | $3.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 8 companies. The companies reported $902,451 in research payments for these studies, mostly to the institutions running them.
- A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
Pfizer Inc. - CHS11402
Coherus Oncology, Inc. - A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Exelixis Inc. - A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie Inc. · Active, not recruiting · NCT06614192 - A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Ca…
Incyte Corporation - Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
Boehringer Ingelheim Pharma GmbH & Co.kg - Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
Boehringer Ingelheim Pharmaceuticals, Inc. - Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.